Melatonin Treatment Improves Insulin Resistance and Pigmentation in Obese Patients with Acanthosis Nigricans

Hang Sun, Xingchun Wang, Jiaqi Chen, Aaron M Gusdon, Kexiu Song, Liang Li, Shen Qu, Hang Sun, Xingchun Wang, Jiaqi Chen, Aaron M Gusdon, Kexiu Song, Liang Li, Shen Qu

Abstract

Objective: This study aimed to determine the effects of melatonin on insulin resistance in obese patients with acanthosis nigricans (AN).

Methods: A total of 17 obese patients with acanthosis nigricans were recruited in a 12-week pilot open trial. Insulin sensitivity, glucose metabolism, inflammatory factors, and other biochemical parameters before and after the administration of melatonin were measured.

Results: After 12 weeks of treatment with melatonin (3 mg/day), homeostasis model assessment insulin resistance index (HOMA-IR) (8.99 ± 5.10 versus 7.77 ± 5.21, p < 0.05) and fasting insulin (37.09 5 ± 20.26 μU/ml versus 32.10 ± 20.29 μU/ml, p < 0.05) were significantly decreased. Matsuda index (2.82 ± 1.54 versus 3.74 ± 2.02, p < 0.05) was significantly increased. There were also statistically significant declines in the AN scores of the neck and axilla, body weight, body mass index, body fat, visceral index, neck circumference, waist circumference, and inflammatory markers.

Conclusions: It was concluded that melatonin could improve cutaneous symptoms in obese patients with acanthosis nigricans by improving insulin sensitivity and inflammatory status. This trial is registered with ClinicalTrials.gov NCT02604095.

Figures

Figure 1
Figure 1
Effects of melatonin on acanthosis of neck: a typical case. (a) Baseline. (b) After 12 w treatment.

References

    1. Skene D. J., Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2006;43(5):344–353. doi: 10.1258/000456306778520142.
    1. Zhang H. M., Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. Journal of Pineal Research. 2014;57(2):131–146. doi: 10.1111/jpi.12162.
    1. Manchester L. C., Coto-Montes A., Boga J. A., et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. Journal of Pineal Research. 2015;59(4):403–419. doi: 10.1111/jpi.12267.
    1. Mauriz J. L., Collado P. S., Veneroso C., Reiter R. J., González-Gallego J. A review of the molecular aspects of melatonin’s anti-inflammatory actions: recent insights and new perspectives. Journal of Pineal Research. 2013;54(1):1–14. doi: 10.1111/j.1600-079X.2012.01014.x.
    1. Borges Lda S., Dermargos A., da Silva Junior E. P., Weimann E., Lambertucci R. H., Hatanaka E. Melatonin decreases muscular oxidative stress and inflammation induced by strenuous exercise and stimulates growth factor synthesis. Journal of Pineal Research. 2015;58(2):166–172. doi: 10.1111/jpi.12202.
    1. Vriend J., Reiter R. J. Melatonin feedback on clock genes: a theory involving the proteasome. Journal of Pineal Research. 2015;58(1):1–11. doi: 10.1111/jpi.12189.
    1. Lee J. S., Cua D. J. Melatonin lulling Th17 cells to sleep. Cell. 2015;162(6):1212–1214. doi: 10.1016/j.cell.2015.08.054.
    1. Di Bella G., Mascia F., Gualano L., Di Bella L. Melatonin anticancer effects: review. International Journal of Molecular Sciences. 2013;14(2):2410–2430. doi: 10.3390/ijms14022410.
    1. Sun H., Huang F. F., Qu S. Melatonin: a potential intervention for hepatic steatosis. Lipids in Health and Disease. 2015;14(1):p. 75. doi: 10.1186/s12944-015-0081-7.
    1. Peschke E., Bahr I., Muhlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. International Journal of Molecular Sciences. 2013;14(4):6981–7015. doi: 10.3390/ijms14046981.
    1. Espino J., Pariente J. A., Rodriguez A. B. Role of melatonin on diabetes-related metabolic disorders. World Journal of Diabetes. 2011;2(6):82–91. doi: 10.4239/wjd.v2.i6.82.
    1. Srinivasan V., Ohta Y., Espino J., et al. Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. 2013;7(1):11–25. doi: 10.2174/187221413804660953.
    1. Schwartz R. A. Acanthosis nigricans. Journal of the American Academy of Dermatology. 1994;31(1):1–19. doi: 10.1016/S0190-9622(94)70128-8.
    1. Phiske M. M. An approach to acanthosis nigricans. Indian Dermatology Online Journal. 2014;5(3):239–249. doi: 10.4103/2229-5178.137765.
    1. Kobaissi H. A., Weigensberg M. J., Ball G. D., Cruz M. L., Shaibi G. Q., Goran M. I. Relation between acanthosis nigricans and insulin sensitivity in overweight Hispanic children at risk for type 2 diabetes. Diabetes Care. 2004;27(6):1412–1416. doi: 10.2337/diacare.27.6.1412.
    1. Kutlubay Z., Engin B., Bairamov O., Tuzun Y. Acanthosis nigricans: a fold (intertriginous) dermatosis. Clinics in Dermatology. 2015;33(4):466–470. doi: 10.1016/j.clindermatol.2015.04.010.
    1. Bellot-Rojas P., Posadas-Sanchez R., Caracas-Portilla N., et al. Comparison of metformin versus rosiglitazone in patients with acanthosis nigricans: a pilot study. Journal of Drugs in Dermatology. 2006;5:884–889.
    1. Freemark M., Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107(4, article E55) doi: 10.1542/peds.107.4.e55.
    1. Hermanns-Le T., Scheen A., Pierard G. E. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. American Journal of Clinical Dermatology. 2004;5(3):199–203. doi: 10.2165/00128071-200405030-00008.
    1. Szewczyk-Golec K., Wozniak A., Reiter R. J. Inter-relationships of the chronobiotic, melatonin, with leptin and adiponectin: implications for obesity. Journal of Pineal Research. 2015;59(3):277–291. doi: 10.1111/jpi.12257.
    1. Peschke E., Bahr I., Muhlbauer E. Experimental and clinical aspects of melatonin and clock genes in diabetes. Journal of Pineal Research. 2015;59(1):1–23. doi: 10.1111/jpi.12240.
    1. Amstrup A. K., Sikjaer T., Pedersen S. B., Heickendorff L., Mosekilde L., Rejnmark L. Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: a randomized placebo-controlled trial. Clinical Endocrinology. 2016;84(3):342–347. doi: 10.1111/cen.12942.
    1. Burke J. P., Hale D. E., Hazuda H. P., Stern M. P. A quantitative scale of acanthosis nigricans. Diabetes Care. 1999;22(10):1655–1659. doi: 10.2337/diacare.22.10.1655.
    1. Haffner S. M., Kennedy E., Gonzalez C., Miettinen H., Kennedy E., Stern M. P. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care. 1996;19(10):1138–1141. doi: 10.2337/diacare.19.10.1138.
    1. Matsuda M., DeFronzo R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–1470. doi: 10.2337/diacare.22.9.1462.
    1. Sinha S., Schwartz R. A. Juvenile acanthosis nigricans. Journal of the American Academy of Dermatology. 2007;57(3):502–508. doi: 10.1016/j.jaad.2006.08.016.
    1. Hud J. A., Jr., Cohen J. B., Wagner J. M., Cruz P. D., Jr. Prevalence and significance of acanthosis nigricans in an adult obese population. Archives of Dermatology. 1992;128(7):941–944. doi: 10.1001/archderm.1992.01680170073009.
    1. Higgins S. P., Freemark M., Prose N. S. Acanthosis nigricans: a practical approach to evaluation and management. Dermatology Online Journal. 2008;14:p. 2.
    1. Rudman S. M., Philpott M. P., Thomas G. A., Kealey T. The role of IGF-I in human skin and its appendages: morphogen as well as mitogen? The Journal of Investigative Dermatology. 1997;109(6):770–777. doi: 10.1111/1523-1747.ep12340934.
    1. Legros C., Devavry S., Caignard S., et al. Melatonin MT1 and MT2 receptors display different molecular pharmacologies only in the G-protein coupled state. British Journal of Pharmacology. 2014;171(1):186–201. doi: 10.1111/bph.12457.
    1. MacKenzie R. S., Melan M. A., Passey D. K., Witt-Enderby P. A. Dual coupling of MT1 and MT2 melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure. Biochemical Pharmacology. 2002;63(4):587–595. doi: 10.1016/S0006-2952(01)00881-4.
    1. Sartori C., Dessen P., Mathieu C., et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology. 2009;150(12):5311–5317. doi: 10.1210/en.2009-0425.
    1. Picinato M. C., Hirata A. E., Cipolla-Neto J., et al. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. Journal of Pineal Research. 2008;44(1):88–94. doi: 10.1111/j.1600-079X.2007.00493.x.
    1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization Technical Report Series. 2000;894:i–xii.
    1. Tan D. X., Manchester L. C., Fuentes-Broto L., Paredes S. D., Reiter R. J. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obesity Reviews. 2011;12(3):167–188. doi: 10.1111/j.1467-789X.2010.00756.x.
    1. Onat A., Hergenc G., Yuksel H., et al. Neck circumference as a measure of central obesity: associations with metabolic syndrome and obstructive sleep apnea syndrome beyond waist circumference. Clinical Nutrition. 2009;28(1):46–51. doi: 10.1016/j.clnu.2008.10.006.
    1. Ben-Noun L. L., Laor A. Relationship between changes in neck circumference and cardiovascular risk factors. Experimental & Clinical Cardiology. 2006;11(1):14–20.
    1. Hotamisligil G. S. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867. doi: 10.1038/nature05485.
    1. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. The Journal of Clinical Investigation. 1995;95(5):2409–2415. doi: 10.1172/JCI117936.
    1. Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334. doi: 10.1001/jama.286.3.327.
    1. Gale E. A., Beattie S. D., Hu J., Koivisto V., Tan M. H. Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care. 2007;30(12):2989–2992. doi: 10.2337/dc07-0155.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever